NASDAQ:MRKR

Marker Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy MRKR

*Your capital is at risk

$1.45

+0.0300 (+2.11%)

At Close: Jun 03, 2026

Marker Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 8.05M and sold 264.4K MRKR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	8.05M shares
● Sell	264.4K shares
92% Buy Activity Strong Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Szymanska Anna Vice President, Quality	CEO / President	40 000 Value: $18.4K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Loiacono Michael Chief Accounting Officer	Officer	140 000 Value: $64.4K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Koneru Mythili Chief Medical Officer	Officer	160 000 Value: $73.6K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Kim Anthony H. Chief Financial Officer	C-Suite Officer	160 000 Value: $73.6K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Hoang Tsvetelina P Vp, Research And Development	Officer	40 000 Value: $18.4K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Garrett Gerald Vice President, Clinical Ops.	CEO / President	40 000 Value: $18.4K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Agopyan Nadia Vp, Regulatory Affairs	Officer	40 000 Value: $18.4K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Agopyan Nadia Vp, Regulatory Affairs	Officer	40 000 Value: $18.4K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Garrett Gerald Vice President, Clinical Ops.	CEO / President	40 000 Value: $18.4K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Hoang Tsvetelina P Vp, Research And Development	Officer	40 000 Value: $18.4K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Kim Anthony H. Chief Financial Officer	C-Suite Officer	160 000 Value: $73.6K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Koneru Mythili Chief Medical Officer	Officer	160 000 Value: $73.6K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Loiacono Michael Chief Accounting Officer	Officer	140 000 Value: $64.4K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Szymanska Anna Vice President, Quality	CEO / President	40 000 Value: $18.4K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Vera Juan Chief Scientific Officer & COO	C-Suite Officer	160 000 Value: $73.6K
Feb 17, 2022 Buy	Employee Stock Option (right to buy) A-Award	Hoang Peter L. President And CEO	CEO / President	430 000 Value: $197.8K
Dec 08, 2021 Buy	Stock Option (Right to Buy) A-Award	Knobil Katharine Director	Director	125 000 Value: $150.0K
Dec 08, 2021 Buy	Common Stock	Knobil Katharine Director	Director	0 Value: $0
Dec 08, 2021 Buy	Common Stock	Knobil Katharine Director	Director	0 Value: $0
Mar 25, 2021 Buy	Common Stock G-Gift	Eansor Norman David Director	Director	7 142 Value: $0
Mar 25, 2021 Sell	Common Stock G-Gift	Eansor Norman David Director	Director	14 285 Value: $0
Mar 25, 2021 Sell	Common Stock G-Gift	Eansor Norman David Director	Director	14 285 Value: $0
Mar 25, 2021 Buy	Common Stock G-Gift	Eansor Norman David Director	Director	7 142 Value: $0
Mar 16, 2021 Buy	Common Stock P-Purchase	Eansor Norman David Director	Director	14 285 Value: $250.0K
Mar 16, 2021 Buy	Common Stock P-Purchase	Eansor Norman David Director	Director	14 285 Value: $250.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MARKER THERAPEUTICS INC.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill...

Read Full Profile Here